Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
272.58
-1.75 (-0.64%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
December 07, 2024
Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
MarketBeat Week in Review – 12/2 - 12/6
December 07, 2024
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025
Via
MarketBeat
Topics
Economy
Government
Immigration
Exposures
Economy
Immigration
Interest Rates
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
December 06, 2024
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
Via
MarketBeat
13 Healthcare Sector Stocks With Healthy Valuation
December 05, 2024
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty...
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Exposures
US Equities
Is Amgen Still a Top Dividend Stock?
December 05, 2024
Via
The Motley Fool
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
December 02, 2024
Via
The Motley Fool
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
November 27, 2024
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
December 05, 2024
Via
Benzinga
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
December 05, 2024
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.
Via
The Motley Fool
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
December 04, 2024
Via
The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
December 03, 2024
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
Decoding Amgen's Options Activity: What's the Big Picture?
November 20, 2024
Via
Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
November 30, 2024
Via
The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
November 29, 2024
The Nasdaq isn't at a high, but it isn't far off either.
Via
Investor's Business Daily
Topics
Government
Exposures
Political
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
November 29, 2024
Via
The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
November 27, 2024
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via
MarketBeat
Topics
Government
Intellectual Property
Exposures
Intellectual Property
Political
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 26, 2024
Via
Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
November 26, 2024
The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's November meeting minutes.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
November 26, 2024
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.
Via
Benzinga
Pain In Retail
November 26, 2024
It’s been a relatively busy morning for earnings, especially from retailers. Of the ten companies reporting, six topped EPS forecasts, seven beat sales forecasts, but two, Best Buy and Kohl’s lowered...
Via
Talk Markets
Topics
Stocks / Equities
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
November 26, 2024
Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight.
Via
Investor's Business Daily
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
November 26, 2024
Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.
Via
Benzinga
Investing in Pharma Stocks? Check These 3 Things First
November 22, 2024
Via
The Motley Fool
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
November 22, 2024
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.
Via
Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
November 21, 2024
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity?
Via
Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
November 19, 2024
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Via
Benzinga
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
November 18, 2024
Via
Benzinga
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
November 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
November 16, 2024
Its future is bright, but that doesn't mean it'll always be smooth sailing.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.